Original Article
Allelic Loss of Chromosome 1p as a Predictor of Unfavorable Outcome in Patients with Neuroblastoma
N Engl J Med 1996; 334:225-230January 25, 1996
- Abstract
Background
Neuroblastoma is a childhood tumor derived from cells of the neural crest, with a widely variable outcome. Differences in the behavior and prognosis of the tumor suggest that neuroblastoma can be divided into several biologic subgroups. We evaluated the most frequent genetic abnormalities in neuroblastoma to determine their prognostic value.
Methods
We used Southern blot analysis to study the allelic loss of chromosomes 1p, 4p, 11q, and 14q, the duplication of chromosome 17q, and the amplification of the N-myc oncogene in 89 neuroblastomas. We also determined the nuclear DNA content of the tumor cells.
Results
Allelic loss of chromosome 1p, N-myc amplification, and extra copies of chromosome 17q were significantly associated with unfavorable outcomes. In a multivariate analysis, loss of chromosome 1p was the most powerful prognostic factor. It provided strong prognostic information when it was included in multivariate models containing the prognostic factors of age and stage or serum ferritin level and stage. Among the patients with stage I, II, or IVS disease, the mean (±SD) three-year event-free survival was 100 percent in those without allelic loss of chromosome 1p and 34±15 percent in those with such loss; the rates of three-year event-free survival among the patients with stage III and stage IV disease were 53±10 percent and 0 percent, respectively.
Conclusions
The loss of chromosome 1p is a strong prognostic factor in patients with neuroblastoma, independently of age and stage. It reliably identifies patients at high risk in stages I, II, and IVS, which are otherwise clinically favorable. More intensive therapy may be considered in these patients. Patients in stages III and IV with allelic loss of chromosome 1p have a very poor outlook, whereas those without such loss are at moderate risk.
Media in This Article
Figure 1
Autoradiographs Showing Allelic Loss of Chromosome 1p in a Neuroblastoma Specimen.Figure 2
Kaplan–Meier Curves for Event-free Survival.Article Activity
- Article
Neuroblastoma is a childhood cancer that originates in cells of the neural crest. The clinical course of the disease varies widely.1 Patients with localized neuroblastoma (those in stages I and II) have a good prognosis after surgical resection, whereas the majority of patients with stage III or IV neuroblastoma have an adverse outcome despite intensive multimodal therapy. However, disseminated stage IVS neuroblastomas (those that would be classified as stage I or II but for the presence of remote disease confined to the liver, skin, bone marrow, or a combination of these, without radiographically detectable bone metastases) frequently undergo spontaneous regression. Factors such as age, tumor stage, tumor histology, and serum levels of lactate dehydrogenase (LDH) and ferritin are clinically meaningful but imperfect predictors of outcome.2-6 Some patients in stages I, II, and IVS die from progressive disease, for example, whereas a minority of those in stages III and IV can be cured.
Several nonrandom genetic abnormalities have been identified in patients with neuroblastoma. These include allelic loss of chromosomes 1p,7-10 4p (unpublished data), 11q,11 and 14q,7,11,12 indicating loss of function of as yet unknown tumor-suppressor genes contained in those regions. Furthermore, there may be amplification of the N-myc oncogene13-15 and additional copies of part of the long arm of chromosome 17 (17q).16,17 It has been established that amplification of the N-myc oncogene has a strongly unfavorable prognostic value.14,15 A nearly diploid nuclear DNA content has also been shown to correlate with a poor response to chemotherapy and an unfavorable outcome, especially in patients under the age of two years at diagnosis.15-18 In some series, allelic loss of chromosome 1p7,9,19,20 has been associated with a poor outcome, but these results are based on the study of a limited number of patients. The prognostic value of the other genetic abnormalities has not yet been studied in detail. In this study we attempted to estimate the prognostic value of all well-established genetic abnormalities in patients with neuroblastoma.
Methods
Patients and Collection of Samples
We obtained samples of tumor tissue and blood from 101 patients with neuroblastoma. From 1990 through 1994, 77 samples were collected prospectively from the Emma Kinderziekenhuis–Academic Medical Center, the Center of Pediatric Oncology of the Southeastern Netherlands, and the Sophia Kinderziekenhuis (all in the Netherlands) and the University Hospital of Ghent (in Belgium). The study methods were approved by the institutional review board. The tumor samples were snap-frozen in the operating room and stored at -80°C. A further 24 tumor and control samples from the years 1984 through 1990 were obtained retrospectively from the tissue bank of the Emma Kinderziekenhuis–Academic Medical Center. The samples from eight patients were excluded, because less than 60 percent of the tumor cells they contained were histologically recognizable. The status of chromosome 1p could not be assessed in four patients. The group of patients described in this paper thus consisted of the remaining 89 patients.
Clinical Characteristics
All the patients were classified according to the Evans staging system,21 with conventional imaging techniques, metaiodobenzylguanidine (MIBG) scanning, and examination of bone marrow aspirates and biopsy specimens obtained with a trephine. The patients' ages at diagnosis were recorded. Serum ferritin and LDH levels at diagnosis were determined by routine laboratory procedures, with the upper limits of the normal range defined as described elsewhere.2-4 For the serum ferritin level the upper limit was 142 μg per liter,4 and for serum LDH it was 1500 U per liter.2,3 The treatment of stage I and II tumors consisted of surgical resection, followed by chemotherapy only if there was gross residual disease. Stage III and IV tumors were treated with various chemotherapeutic regimens, all of which contained at least an alkylating agent, a platinum derivative, and vinca alkaloids. From 1990 onward, MIBG labeled with iodine-131 was used in the first-line treatment of unresectable stage III or IV tumors. Patients with stage IVS tumors were treated only if they had life-threatening symptoms or when there were signs of tumor progression.
Genetic Analysis
Extraction of high-molecular-weight DNA, digestion with appropriate endonucleases, Southern blot analysis, and hybridization with DNA probes were performed as described elsewhere.8 The number of copies of N-myc per haploid genome was determined by densitometric analysis of filters hybridized with a probe for exon 2 of N-myc (pNb1)13 and a control probe, as described elsewhere.8 In the genetic analysis of chromosome 1p, we used the following combinations of polymorphic probes and enzymes: CEB15 and TaqI at locus D1S172 and MS1 or MUc1 and TaqI at locus D1S7. In the analysis of chromosome 4p we used H5.52 and MspI at D4S10, p157.9 and PstI at D4S111, pYNZ32 and TaqI at D4S125, and CEB61 and TaqI at D4S1100. To study chromosome 11q we used pMCT28.1 and MspI at D11S144 and SS6 and TaqI at INT2. To study chromosome 14q we used pAW101 and EcoRI plus TaqI at D14S1, pMLJ14 and TaqI at D14S13, cKKA39 and TaqI at D14S23, and pAT6.5 and AvaII plus TaqI at PI. Loss of an allele at an informative locus was examined by densitometric analysis, as described elsewhere.8 To determine whether additional copies of the long arm of chromosome 17 were present, we used CMM86 and TaqI at locus D17S74, THH59 and TaqI at D17S4, and RMU3 and TaqI at D17S24, following the same densitometric procedure. We determined nuclear DNA content by analyzing propidium iodine–stained suspensions of tumor nuclei, with fluorescence-activated cell sorting, using a modification of the method of Hedley et al.22
Statistical Analysis
The statistical end points in our analyses were event-free survival and overall survival. The events we studied were the recurrence of disease after the attainment of complete remission and the progression of disease during therapy. We calculated univariate hazard ratios with 95 percent confidence intervals, using the Cox proportional-hazards model.23 The simultaneous prognostic effect of various factors was determined in a multivariate analysis with the Cox proportional-hazards model.23 The probability of event-free survival was plotted over time according to specific prognostic factors with Kaplan–Meier life tables.24 Differences between groups in event-free survival were tested with log-rank statistics.
Results
Characteristics of the Patients
Table 1Table 1
Clinical Characteristics of 89 Patients with Neuroblastoma, According to Chromosome 1p Status. shows the clinical characteristics of the 89 patients and the association of these features with the allelic loss of chromosome 1p. Fifty-two patients (58 percent) had stage III or IV neuroblastoma, and 37 patients (42 percent) had localized or stage IVS disseminated tumors. Thirty-seven patients (42 percent) were less than one year old at diagnosis. Thirty-two of 78 patients tested (41 percent) had elevated serum ferritin levels, and 11 of 87 patients tested (13 percent) had serum LDH levels over 1500 U per liter.Genetic Analysis
We used Southern blot analysis to study allelic loss or gain in several chromosomal regions (i.e., 1p, 4p, 11q, 14q, and 17q) and determine the presence or absence of N-myc amplification. The principal findings and their associations with the allelic loss of chromosome 1p are shown in Table 2Table 2
Genetic Findings According to Chromosome 1p Status in Samples of Tumor Tissue from 89 Patients with Neuroblastoma.. Allelic loss of chromosome 1p was found in 29 of the 89 patients (33 percent; an example of such loss is shown in Figure 1Figure 1Autoradiographs Showing Allelic Loss of Chromosome 1p in a Neuroblastoma Specimen.). Allelic loss of chromosome 1p was independent of the patient's age or tumor stage but correlated significantly with increased serum levels of ferritin or LDH (Table 1). N-myc amplification was demonstrated in 17 of the 89 tumor samples (19 percent) (Table 2). All the patients with N-myc amplification also had allelic loss of chromosome 1p. Thirty-one of 74 patients for whom there were data (42 percent) were found to have one or more additional copies of chromosome 17q. These chromosomal gains occurred significantly more often in the patients with allelic loss of chromosome 1p. There were allelic losses of chromosome 4p in 18 of 78 patients for whom data were available (23 percent), of chromosome 11q in 12 of 58 patients (21 percent), and of chromosome 14q in 15 of 71 patients (21 percent). None of these changes were significantly associated with allelic loss of chromosome 1p or any other genetic variables studied. Furthermore, allelic loss of chromosome 4p, 11q, or 14q and duplication of chromosome 17q were not significantly correlated with age, tumor stage, or serum level of ferritin or LDH. A nuclear DNA content in the normal range (i.e., indicating a nearly diploid tumor) was found in 55 percent of the tumors studied, and a higher (i.e., aneuploid) DNA content in 45 percent. Significantly more of the patients with nearly diploid tumors had N-myc amplification, allelic loss of chromosome 1p, and extra copies of chromosome 17q. Nearly diploid DNA content was also found significantly more often in stage III and IV tumors.Relation of Clinical and Genetic Factors to Outcome
We analyzed the ability of the various clinical and genetic factors to predict clinical outcome. The analyses of event-free survival and overall survival yielded similar results, reflecting the very small possibility of a favorable outcome in patients with recurrent neuroblastoma. We therefore report the results of the analysis of event-free survival, because that end point reflects tumor behavior more directly than does overall survival. The mean period of follow-up for the entire group of patients was 40 months.
We calculated univariate hazard ratios with the proportional-hazards model (Table 3Table 3
Hazard Ratios Associated with Individual Genetic and Clinical Prognostic Factors in 89 Patients with Neuroblastoma.). In this analysis, all four clinical variables studied had significant prognostic value. Among the genetic variables, allelic loss of chromosome 4p, 11q, or 14q had no prognostic value. Allelic loss of chromosome 1p and N-myc amplification were each associated with a high likelihood of an unfavorable outcome. In addition, extra copies of chromosome 17q and, to a lesser extent, nearly diploid nuclear DNA content were each associated with a bad prognosis.Multivariate Analysis
Several genetic and clinical factors with significant prognostic value were interrelated in their ability to predict clinical outcome (Table 1 and Table 2). To identify the most powerful prognostic factors, we performed multivariate analyses with the Cox proportional-hazards model. The hazard ratios calculated with two models using clinical variables are shown in Table 4Table 4
Hazard Ratios Associated with Clinical and Genetic Prognostic Factors in a Multivariate Analysis of 89 Patients with Neuroblastoma, Using Cox Proportional-Hazards Models.. The first model contained age and tumor stage, the prognostic factors in widest use. The second model contained tumor stage and serum ferritin level, because that combination gave the best fit attainable with any combination of the four clinical prognostic factors. Adding age or serum LDH level to the second model yielded no additional prognostic information, an indication that serum ferritin levels correlate with age but provide more prognostic information.To test whether including any of the genetic factors would add prognostic information, we included each one in both models (data not shown). N-myc status and chromosome 1p status each contributed significant prognostic information to both models. When we added the presence of extra copies of chromosome 17q to both models, we obtained some additional prognostic information, but this effect disappeared when either allelic loss of chromosome 1p or N-myc amplification was subsequently added to the model. Nearly diploid nuclear DNA content provided no significant prognostic information when that factor was added to either model, indicating that the prognostic value it demonstrated on univariate analysis was redundant with the prognostic value of the clinical factors.
Superior Prognostic Value of Allelic Loss of Chromosome 1p
We performed further multivariate analyses to explore the prognostic value of the allelic loss of chromosome 1p relative to that of N-myc amplification. The simultaneous addition of chromosome 1p status and N-myc status to the second Cox model showed that 1p status had the strongest predictive power when tested together with the other three factors (Table 4). When combined with loss of chromosome 1p, N-myc amplification lost its prognostic power. This indicates that allelic loss of chromosome 1p is superior to N-myc amplification as a prognostic factor. Allelic loss of chromosome 1p was found in all patients with N-myc amplification, and thus it identified the same patients at high risk as that factor. However, allelic loss of chromosome 1p was also found in patients with a single copy of N-myc (i.e., without amplification), and it predicted their unfavorable outcome. For these patients the univariate hazard ratio associated with allelic loss of chromosome 1p was 3.9 (95 percent confidence interval, 1.6 to 9.6; P=0.003), and they had a three-year rate of event-free survival of 35±15 percent. Among patients with both allelic loss of chromosome 1p and N-myc amplification, the corresponding rate was 0 percent.
Prognostic Value of Allelic Loss of Chromosome 1p Regardless of Age or Tumor Stage
To gain more insight into the effect of allelic loss of chromosome 1p on clinical outcome we analyzed event-free survival according to chromosome 1p status among patients of differing stages and ages. The predicted rate of event-free survival for three years among patients in stages I, II, and IVS was 83±6 percent, as compared with 30±7 percent among patients in stages III and IV (P = 0.002) (Figure 2AFigure 2
Kaplan–Meier Curves for Event-free Survival.). Among patients with allelic loss of chromosome 1p, the rate of event-free survival for three years was 12±7 percent, as compared with 75±6 percent among those in whom no such loss was detectable (P<0.001) (Figure 2B). Among patients with stage I, II, or IVS disease, loss of chromosome 1p identified those in whom standard treatment was most likely to fail (three-year event-free survival, 34±15 percent) (Figure 2C). The remaining patients in these disease stages, who did not have allelic loss of chromosome 1p, all survived for three years without events (P<0.001). Among patients with stage III or IV disease, loss of chromosome 1p defined a very-high-risk group, none of whose members survived for three years free of events, whereas among those who did not have such loss the three-year event-free survival was 53±10 percent (P<0.001) (Figure 2D).Among the 52 patients one year old or older, none of the 17 who had 1p loss in their tumors survived without events for three years, whereas the rate of three-year event-free survival was 52±9 percent in the 35 who did not have 1p loss (P<0.001). Among the 37 patients less than one year old, the three-year event-free survival in the 12 with allelic loss of 1p was 32±15 percent, as compared with 100 percent in the 25 without such loss (P<0.001).
The group of patients with N-myc amplification was a subgroup of the patients with 1p loss. Therefore, the patients without N-myc amplification constituted a group in which loss of chromosome 1p had additional prognostic value. The clinical characteristics of these two groups with allelic loss of chromosome 1p differed. N-myc amplification occurred together with 1p loss mainly in patients with stage III or IV disease (16 of 17 patients) and in patients one year old or older (13 of 17 patients). Among the 72 patients without N-myc amplification, 12 (17 percent) had allelic loss of chromosome 1p. Three of these 12 patients had stage IV tumors and were one year old or older. The remaining nine patients, who had 1p loss but no N-myc amplification, had stage I, II, or IVS neuroblastomas, and eight of these patients were less than one year old. This shows that among the patients without N-myc amplification, most of those at high risk who were identified on the basis of allelic loss of chromosome 1p were under the age of one year and had stage I, II, or IVS tumors.
Discussion
Our study found that allelic loss of chromosome 1p is a powerful prognostic indicator in patients with neuroblastoma. Univariate testing showed that four genetic variables (allelic loss of chromosome 1p, N-myc amplification, extra copies of chromosome 17q, and a nearly diploid nuclear DNA content) were significant predictors of unfavorable outcome. The prognostic value of N-myc amplification in neuroblastoma is well established.14,15 In this study, allelic loss of chromosome 1p was found to be a better prognostic indicator than N-myc amplification. The latter was present in a subgroup of patients whose tumors had allelic loss of chromosome 1p. Moreover, patients whose neuroblastomas had a single copy of N-myc and allelic loss of chromosome 1p were at high risk for an unfavorable outcome. The presence of extra copies of chromosome 17q and nearly diploid nuclear DNA content were of only minor prognostic significance as compared with allelic loss of chromosome 1p and N-myc amplification.
The main clinical value of allelic loss of chromosome 1p as a prognostic factor lies in its ability to detect patients at high risk among those who do not have N-myc amplification. For patients with stage I, II, or IVS disease, N-myc amplification was a rare event and was not present in the majority of patients with an unfavorable outcome. Patients with stage I, II, or IVS disease who had 1p loss (12 percent of the patients in this series) were at a higher risk for recurrence than those who did not have such loss (three-year event-free survival, 34 percent vs. 100 percent). In patients such as the former, more aggressive therapy at diagnosis may be considered. Patients with stage I, II, or IVS disease without allelic loss of chromosome 1p (30 percent of the patients in this series) had an excellent prognosis (three-year event-free survival, 100 percent). In this group of patients, therapy should be as minimal as possible and should be viewed in the light of possible late effects. Among patients in stages III and IV, additional patients at very high risk who did not have N-myc amplification were identified on the basis of 1p loss. However, in this group the additional prognostic value of 1p loss was limited, because most of the patients at very high risk had N-myc amplification together with allelic loss of chromosome 1p. The current intensive multimodal therapy may be especially useful for patients with stage III or IV disease but no 1p loss, whereas more innovative therapeutic approaches may be justified in patients with stage III and IV disease who have such loss.
The association between allelic loss of 1p and outcome has been described in three other studies. Fong et al.7 described five patients without N-myc amplification who had allelic loss of chromosome 1p, three of whom remained disease-free for more than three years. Ambros et al.20 studied 42 stage I and II neuroblastomas with single copies of N-myc. Among the 5 patients with 1p loss, 3 had recurrences, as compared with 1 of the remaining 37 patients without such loss. Takeda et al.9 described four patients with allelic loss of 1p and no N-myc amplification who had a relatively short mean follow-up of 15 months and did not have events. In our series, the 12 patients with allelic loss of chromosome 1p and a single copy of the N-myc gene had a relative risk of recurrent disease of 3.9, with a three-year event-free survival of 35 percent. Taken together, these data indicate that allelic loss of chromosome 1p identifies more patients who are likely to have an unfavorable outcome than does N-myc amplification alone. However, some patients whose tumors have allelic loss of chromosome 1p and a single copy of the N-myc gene are long-term survivors. Thus, the principal advantage of using allelic loss of chromosome 1p as a prognostic factor is in identifying high-risk patients among those with single copies of N-myc, the majority of whom have stage I, II, or IVS neuroblastomas.
Supported by grants from the Stichting Kindergeneeskundig Kankeronderzoek and the Dutch Cancer Society.
We are indebted to J. Groot-Loonen, K. Hählen, H. Hey, R. Lippens, K. Moorman-Voestermans, Y. Meijer, N. Schouten-van Meeteren, and M. van Weel for providing blood and tumor samples; to J.H. Bras for assistance with the histologic analyses; to A.J.M. de Craen for assistance with the statistical analysis; and to J. Armour, A. Frischauf, M. Schwab, G. Vergnaud, the Japanese Cancer Resources Bank, and the American Type Culture Collection for making DNA probes available to us.
Source Information
From the Department of Pediatric Oncology and Hematology, Emma Kinderziekenhuis–Academic Medical Center (H.C., J.K., P.A.V.), and the Institute of Human Genetics, Academic Medical Center (H.C., P.S., R.S., A.W., R.V.), University of Amsterdam, Amsterdam; the Center of Pediatric Oncology of the Southeastern Netherlands, University of Nijmegen, Nijmegen (J.B.); and the Sophia Kinderziekenhuis, Erasmus University, Rotterdam (M.E.) — all in the Netherlands; and the Institute of Human Genetics, University Hospital of Ghent, Ghent, Belgium (G.L.).
Address reprint requests to Dr. Caron at the Department of Pediatric Oncology and Hematology, EKZ/AMC, P.O. Box 22700, 1100 DE Amsterdam, the Netherlands.
- References
References
1
Voûte PA, de Kraker J, Hoefnagel CA. Tumors of the sympathetic nervous system: neuroblastoma, ganglioneuroma and phaeochromocytoma. In: Voûte PA, Barrett A, Lemerle J, eds. Cancer in children: clinical management. 3rd ed. Berlin, Germany: Springer-Verlag, 1992.
2
Berthold F ,Trechow R ,Utsch S ,Zieschang J . Prognostic factors in metastatic neuroblastoma: a multivariate analysis of 182 cases. Am J Pediatr Hematol Oncol 1992;14:207-215
CrossRef | Medline3
Shuster JJ ,McWilliams NB ,Castleberry R , et al. Serum lactate dehydrogenase in childhood neuroblastoma: a Pediatric Oncology Group recursive partitioning study. Am J Clin Oncol 1992;15:295-303
CrossRef | Web of Science | Medline4
Silber JH ,Evans AE ,Fridman M . Models to predict outcome from childhood neuroblastoma: the role of serum ferritin and tumor histology. Cancer Res 1991;51:1426-1433
Web of Science | Medline5
Shimada H ,Chatten J ,Newton WA Jr . Histopathologic prognostic factors in neuroblastic tumors: definition of subtypes of ganglioneuroblastoma and an age-linked classification of neuroblastomas. J Natl Cancer Inst 1984;73:405-416
Web of Science | Medline6
Joshi VV ,Cantor AB ,Altshuler G , et al. Age-linked prognostic categorization based on a new histologic grading system of neuroblastomas: a clinicopathologic study of 211 cases from the Pediatric Oncology Group. Cancer 1992;69:2197-2211
CrossRef | Web of Science | Medline7
Fong CT ,White PS ,Peterson K , et al. Loss of heterozygosity for chromosomes 1 or 14 defines subsets of advanced neuroblastomas. Cancer Res 1992;52:1780-1785
Web of Science | Medline8
Caron HN ,van Sluis P ,van Hoeve M , et al. Allelic loss of chromosome 1p36 in neuroblastoma is of preferential maternal origin and correlates with N-myc amplification. Nat Genet 1993;4:187-190[Erratum, Nat Genet 1993;4:431.]
CrossRef | Web of Science | Medline9
Takeda O ,Homma C ,Maseki N , et al. There may be two tumor suppressor genes on chromosome arm 1p closely associated with biologically distinct subtypes of neuroblastoma. Genes Chromosomes Cancer 1994;10:30-39
CrossRef | Web of Science | Medline10
Schleiermacher G ,Peter M ,Michon J , et al. Two distinct deleted regions on the short arm of chromosome 1 in neuroblastoma. Genes Chromosomes Cancer 1994;10:275-281
CrossRef | Web of Science | Medline11
Srivatsan ES ,Murali V ,Seeger RC . Loss of heterozygosity for alleles on chromosomes 11q and 14q in neuroblastoma. Prog Clin Biol Res 1991;366:91-98
Medline12
Suzuki T ,Yokota J ,Mugishima H , et al. Frequent loss of heterozygosity on chromosome 14q in neuroblastoma. Cancer Res 1989;49:1095-1098
Web of Science | Medline13
Schwab M ,Alitalo K ,Klempnauer KH , et al. Amplified DNA with limited homology to myc cellular oncogene is shared by human neuroblastoma cell lines and a neuroblastoma tumor. Nature 1983;305:245-248
CrossRef | Web of Science | Medline14
Seeger RC ,Brodeur GM ,Sather H , et al. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastoma. N Engl J Med 1985;313:1111-1116
Full Text | Web of Science | Medline15
Bourhis J ,De Vathaire F ,Wilson GD , et al. Combined analysis of DNA ploidy index and N-myc genomic content in neuroblastoma. Cancer Res 1991;51:33-36
Web of Science | Medline16
Van Roy N ,Laureys G ,Cheng NC , et al. 1;17 Translocations and other chromosome 17 rearrangements in human primary neuroblastoma tumors and cell lines. Genes Chromosomes Cancer 1994;10:103-114
CrossRef | Web of Science | Medline17
Caron HN ,van Sluis P ,van Roy N , et al. Recurrent 1;17 translocations in human neuroblastomas reveal nonhomologous mitotic recombination during the S/G2 phase as a novel mechanism for loss of heterozygosity. Am J Hum Genet 1994;55:341-347
Web of Science | Medline18
Look AT ,Hayes FA ,Nitschke R ,McWilliams NB ,Green AA . Cellular DNA content as a predictor of response to chemotherapy in infants with unresectable neuroblastoma. N Engl J Med 1984;311:231-235
Full Text | Web of Science | Medline19
Caron HN . Allelic loss of chromosome 1 and additional chromosome 17 material are both unfavourable prognostic markers in neuroblastoma. Med Pediatr Oncol 1995;24:215-221
CrossRef | Medline20
Ambros PF ,Ambros IM ,Strehl S , et al. Regression and progression in neuroblastoma: does genetics predict tumor behaviour? Eur J Cancer 1995;31:510-516
CrossRef | Web of Science21
Evans AE ,D'Angio GJ ,Randolph J . A proposed staging system for children with neuroblastoma: children's cancer study group A. Cancer 1971;27:374-378
CrossRef | Web of Science | Medline22
Hedley DW ,Friedlander ML ,Taylor IW ,Rugg CA ,Musgrove EA . Method for analysis of cellular DNA content of paraffin-embedded pathological material using flow cytometry. J Histochem Cytochem 1983;31:1333-1335
CrossRef | Web of Science | Medline23
Campos-Filho N ,Franco EL . Microcomputer-assisted univariate survival data analysis using Kaplan-Meier life table estimators. Comput Methods Programs Biomed 1988;27:223-228
CrossRef | Web of Science | Medline24
Campos-Filho N ,Franco EL . A microcomputer program for multiple logistic regression by unconditional and conditional maximum likelihood methods. Am J Epidemiol 1989;129:439-444
Web of Science | Medline
- Citing Articles (131)
Citing Articles
1
Peter E. Zage, Andrew J. Bean. (2012) Growth factor receptor trafficking as a potential therapeutic target in pediatric cancer. Frontiers in Biology 7:1, 1-13
CrossRef2
Ingrid Øra, Angelika Eggert. (2011) Progress in treatment and risk stratification of neuroblastoma: Impact on future clinical and basic research. Seminars in Cancer Biology 21:4, 217-228
CrossRef3
Marta Jeison, Isaac Yaniv, Shifra Ash. (2011) Genetic stratification of neuroblastoma for treatment tailoring. Future Oncology 7:9, 1087-1099
CrossRef4
G. M. Brodeur. (2011) Knowing Your ABCCs: Novel Functions of ABCC Transporters. JNCI Journal of the National Cancer Institute 103:16, 1207-1208
CrossRef5
Vincenza Rita Lo Vasco. (2011) 1p36.32 rearrangements and the role of PI-PLC η2 in nervous tumours. Journal of Neuro-Oncology 103:3, 409-416
CrossRef6
Naoki Mori, Kentaro Yoshinaga, Kaori Tomita, Mari Ohwashi, Toshiaki Kondoh, Hanae Shimura, Yan-Hua Wang, Masayuki Shiseki, Michiko Okada, Toshiko Motoji. (2011) Aberrant methylation of the RIZ1 gene in myelodysplastic syndrome and acute myeloid leukemia. Leukemia Research 35:4, 516-521
CrossRef7
Rebecca J. Deyell, Edward F. Attiyeh. (2011) Advances in the understanding of constitutional and somatic genomic alterations in neuroblastoma. Cancer Genetics 204:3, 113-121
CrossRef8
Federica Parodi, Lorena Passoni, Luisa Massimo, Roberto Luksch, Claudio Gambini, Elena Rossi, Orsetta Zuffardi, Vito Pistoia, Annalisa Pezzolo. (2011) Identification of Novel Prognostic Markers in Relapsing Localized Resectable Neuroblastoma. OMICS: A Journal of Integrative Biology 15:3, 113-121
CrossRef9
Blanca Molina, Laura Alonso, Marta Gonzalez-Vicent, Maitane Andion, Carmen Hernandez, Alvaro Lassaletta, Maria Cormenzana, Blanca Lopez-Ibor, Marta Villa, Javier Molina, Miguel A. Diaz. (2011) High-Dose Busulfan and Melphalan as Conditioning Regimen for Autologous Peripheral Blood Progenitor Cell Transplantation in High-Risk Neuroblastoma Patients. Pediatric Hematology-Oncology 28:2, 115-123
CrossRef10
Sucheta J. Vaidya, Andrew D. J. Pearson. 2010. Neuroblastoma. , 163-192.
CrossRef11
Baker, David L., Schmidt, Mary L., Cohn, Susan L., Maris, John M., London, Wendy B., Buxton, Allen, Stram, Daniel, Castleberry, Robert P., Shimada, Hiroyuki, Sandler, Anthony, Shamberger, Robert C., Look, A. Thomas, Reynolds, C. Patrick, Seeger, Robert C., Matthay, Katherine K., . (2010) Outcome after Reduced Chemotherapy for Intermediate-Risk Neuroblastoma. New England Journal of Medicine 363:14, 1313-1323
Full Text12
R M Parry, W Jones, T H Stokes, J H Phan, R A Moffitt, H Fang, L Shi, A Oberthuer, M Fischer, W Tong, M D Wang. (2010) k-Nearest neighbor models for microarray gene expression analysis and clinical outcome prediction. The Pharmacogenomics Journal 10:4, 292-309
CrossRef13
Michael Hölzel, Sidong Huang, Jan Koster, Ingrid Øra, Arjan Lakeman, Huib Caron, Wouter Nijkamp, Jing Xie, Tom Callens, Shahab Asgharzadeh, Robert C. Seeger, Ludwine Messiaen, Rogier Versteeg, René Bernards. (2010) NF1 Is a Tumor Suppressor in Neuroblastoma that Determines Retinoic Acid Response and Disease Outcome. Cell 142:2, 218-229
CrossRef14
Z. Li, F. Tan, D. J. Liewehr, S. M. Steinberg, C. J. Thiele. (2010) In Vitro and In Vivo Inhibition of Neuroblastoma Tumor Cell Growth by AKT Inhibitor Perifosine. JNCI Journal of the National Cancer Institute 102:11, 758-770
CrossRef15
Marta Jeison, Shifra Ash, Gili Halevy-Berko, Jacques Mardoukh, Drorit Luria, Smadar Avigad, Galina Feinberg-Gorenshtein, Yacov Goshen, Gabriel Hertzel, Joseph Kapelushnik, Ayelet Ben Barak, Dina Attias, Ran Steinberg, Jerry Stein, Batia Stark, Isaac Yaniv. (2010) 2p24 Gain Region Harboring MYCN Gene Compared with MYCN Amplified and Nonamplified Neuroblastoma. The American Journal of Pathology 176:6, 2616-2625
CrossRef16
Jörn Bullerdiek, David Gisselsson. 2010. Tumors of Endocrine Glands. , 577-596.
CrossRef17
Julie R. Park, Angelika Eggert, Huib Caron. (2010) Neuroblastoma: Biology, Prognosis, and Treatment. Hematology/Oncology Clinics of North America 24:1, 65-86
CrossRef18
K. Schmalisch, T. Psaras, R. Beschorner, J. Honegger. (2009) Sellar neuroblastoma mimicking a pituitary tumour: Case report and review of the literature. Clinical Neurology and Neurosurgery 111:9, 774-778
CrossRef19
Hari R Kumar, Xiaoling Zhong, Frederick J Rescorla, Robert J Hickey, Linda H Malkas, John A Sandoval. (2009) Proteomic approaches in neuroblastoma: a complementary clinical platform for the future. Expert Review of Proteomics 6:4, 387-394
CrossRef20
Stefan Fest, Nicole Huebener, Matthias Bleeke, Tahir Durmus, Alexander Stermann, Anja Woehler, Bianca Baykan, Ana C. Zenclussen, Elke Michalsky, Ines S. Jaeger, Robert Preissner, Oliver Hohn, Silke Weixler, Gerhard Gaedicke, Holger N. Lode. (2009) Survivin minigene DNA vaccination is effective against neuroblastoma. International Journal of Cancer 125:1, 104-114
CrossRef21
P F Ambros, I M Ambros, G M Brodeur, M Haber, J Khan, A Nakagawara, G Schleiermacher, F Speleman, R Spitz, W B London, S L Cohn, A D J Pearson, J M Maris. (2009) International consensus for neuroblastoma molecular diagnostics: report from the International Neuroblastoma Risk Group (INRG) Biology Committee. British Journal of Cancer 100:9, 1471-1482
CrossRef22
Marta Piqueras, Samuel Navarro, Victoria Castel, Adela Cañete, Antonio Llombart-Bosch, Rosa Noguera. (2009) Analysis of biological prognostic factors using tissue microarrays in neuroblastic tumors. Pediatric Blood & Cancer 52:2, 209-214
CrossRef23
Bertrand Isidor, Martine Le Cunff, Michelle Boceno, Pierre Boisseau, Caroline Thomas, Jean-Marie Rival, Albert David, Cédric Le Caignec. (2008) Complex constitutional subtelomeric 1p36.3 deletion/duplication in a mentally retarded child with neonatal neuroblastoma. European Journal of Medical Genetics 51:6, 679-684
CrossRef24
Eva Villamón, Marta Piqueras, Carlos Mackintosh, Javier Alonso, Enrique Álava, Samuel Navarro, Rosa Noguera. (2008) Comparison of different techniques for the detection of genetic risk-identifying chromosomal gains and losses in neuroblastoma. Virchows Archiv 453:1, 47-55
CrossRef25
Emine Kilic, Hennie T. Brüggenwirth, Marit Meier, Nicole C. Naus, H. Berna Beverloo, Jules P. Meijerink, Gre P. Luyten, Annelies de Klein. (2008) Increased expression of p73Δex2 transcript in uveal melanoma with loss of chromosome 1p. Melanoma Research 18:3, 208-213
CrossRef26
Julie R. Park, Angelika Eggert, Huib Caron. (2008) Neuroblastoma: Biology, Prognosis, and Treatment. Pediatric Clinics of North America 55:1, 97-120
CrossRef27
M Łastowska, V Viprey, M Santibanez-Koref, I Wappler, H Peters, C Cullinane, P Roberts, A G Hall, D A Tweddle, A D J Pearson, I Lewis, S A Burchill, M S Jackson. (2007) Identification of candidate genes involved in neuroblastoma progression by combining genomic and expression microarrays with survival data. Oncogene 26:53, 7432-7444
CrossRef28
H Carén, S Fransson, K Ejeskär, P Kogner, T Martinsson. (2007) Genetic and epigenetic changes in the common 1p36 deletion in neuroblastoma tumours. British Journal of Cancer 97:10, 1416-1424
CrossRef29
Loïc de Pontual, Delphine Trochet, Franck Bourdeaut, Sophie Thomas, Heather Etchevers, Agnes Chompret, Véronique Minard, Dominique Valteau, Laurence Brugieres, Arnold Munnich, Olivier Delattre, Stanislas Lyonnet, Isabelle Janoueix-Lerosey, Jeanne Amiel. (2007) Methylation-associated PHOX2B gene silencing is a rare event in human neuroblastoma. European Journal of Cancer 43:16, 2366-2372
CrossRef30
Suguru Fukahori, Hirohisa Yano, Makoto Tsuneoka, Yoshiaki Tanaka, Minoru Yagi, Michihiko Kuwano, Tatsuro Tajiri, Tomoaki Taguchi, Masazumi Tsuneyoshi, Masamichi Kojiro. (2007) Immunohistochemical expressions of Cap43 and Mina53 proteins in neuroblastoma. Journal of Pediatric Surgery 42:11, 1831-1840
CrossRef31
V. Castel, E. Grau, R. Noguera, F. Martínez. (2007) Molecular biology of neuroblastoma. Clinical and Translational Oncology 9:8, 478-483
CrossRef32
G Schleiermacher, J Michon, I Huon, C Dubois d'Enghien, J Klijanienko, H Brisse, A Ribeiro, V Mosseri, H Rubie, C Munzer, C Thomas, D Valteau-Couanet, A Auvrignon, D Plantaz, O Delattre, J Couturier. (2007) Chromosomal CGH identifies patients with a higher risk of relapse in neuroblastoma without MYCN amplification. British Journal of Cancer 97:2, 238-246
CrossRef33
John M Maris, Michael D Hogarty, Rochelle Bagatell, Susan L Cohn. (2007) Neuroblastoma. The Lancet 369:9579, 2106-2120
CrossRef34
Christine L. O'Keefe, Ramon Tiu, Lukasz P. Gondek, Jennifer Powers, Karl S. Theil, Matt Kalaycio, Alan Lichtin, Mikkael A. Sekeres, Jaroslaw P. Maciejewski. (2007) High-Resolution Genomic Arrays Facilitate Detection of Novel Cryptic Chromosomal Lesions in Myelodysplastic Syndromes. Experimental Hematology 35:2, 240-251
CrossRef35
Jane Carr, Nick P. Bown, Marian C. Case, Andrew G. Hall, John Lunec, Deborah A. Tweddle. (2007) High-resolution analysis of allelic imbalance in neuroblastoma cell lines by single nucleotide polymorphism arrays. Cancer Genetics and Cytogenetics 172:2, 127-138
CrossRef36
Oguz Altungoz, Nevim Aygun, Sait Tumer, Erdener Ozer, Nur Olgun, Meral Sakizli. (2007) Correlation of modified Shimada classification with MYCN and 1p36 status detected by fluorescence in situ hybridization in neuroblastoma. Cancer Genetics and Cytogenetics 172:2, 113-119
CrossRef37
Octavio Burgues, Samuel Navarro, Rosa Noguera, Antonio Pellín, Amparo Ruiz, Victoria Castel, Antonio Llombart-Bosch. (2006) Prognostic value of the International Neuroblastoma Pathology Classification in Neuroblastoma (Schwannian stroma-poor) and comparison with other prognostic factors: a study of 182 cases from the Spanish Neuroblastoma Registry. Virchows Archiv 449:4, 410-420
CrossRef38
B Yan, H Wang, H Wang, D Zhuo, F Li, T Kon, M Dewhirst, C-Y Li. (2006) Apoptotic DNA fragmentation factor maintains chromosome stability in a P53-independent manner. Oncogene 25:39, 5370-5376
CrossRef39
Thorsten Simon, Rüdiger Spitz, Barbara Hero, Frank Berthold, Andreas Faldum. (2006) Risk estimation in localized unresectable single copy MYCN neuroblastoma by the status of chromosomes 1p and 11q. Cancer Letters 237:2, 215-222
CrossRef40
Massimo Conte, Stefano Parodi, Bruno De Bernardi, Claudia Milanaccio, Katia Mazzocco, Paola Angelini, Elisabetta Viscardi, Andrea Di Cataldo, Roberto Luksch, Riccardo Haupt. (2006) Neuroblastoma in adolescents. Cancer 106:6, 1409-1417
CrossRef41
Yasuhiko Kaneko, Hirofumi Kobayashi, Naoki Watanabe, Nobumoto Tomioka, Akira Nakagawara. (2006) Biology of neuroblastomas that were found by mass screening at 6 months of age in Japan. Pediatric Blood & Cancer 46:3, 285-291
CrossRef42
K B Grandinetti, B A Spengler, J L Biedler, R A Ross. (2006) Loss of one HuD allele on chromosome #1p selects for amplification of the N-myc proto-oncogene in human neuroblastoma cells. Oncogene 25:5, 706-712
CrossRef43
John Matthew Maris. 2006. Neuroblastoma. .
CrossRef44
Marieke Aarts, Hilde Dannenberg, Ronald J. deLeeuw, Francien H. van Nederveen, Albert A. Verhofstad, J. W. Lenders, Winand N. M. Dinjens, Ernst Jan M. Speel, Wan L. Lam, Ronald R. de Krijger. (2006) Microarray-based CGH of sporadic and syndrome-related pheochromocytomas using a 0.1-0.2 Mb bacterial artificial chromosome array spanning chromosome arm 1p. Genes, Chromosomes and Cancer 45:1, 83-93
CrossRef45
Attiyeh, Edward F., London, Wendy B., Mossé, Yael P., Wang, Qun, Winter, Cynthia, Khazi, Deepa, McGrady, Patrick W., Seeger, Robert C., Look, A. Thomas, Shimada, Hiroyuki, Brodeur, Garrett M., Cohn, Susan L., Matthay, Katherine K., Maris, John M., . (2005) Chromosome 1p and 11q Deletions and Outcome in Neuroblastoma. New England Journal of Medicine 353:21, 2243-2253
Full Text46
Mehmet Fatih Okcu, Rui-Yu Wang, Carlos Bueso-Ramos, Wendy Schober, Douglas Weidner, Richard Andrassy, Martin Blakely, Heidi Russell, Alp Ozkan, John Kuttesch, Michael Andreeff, Ka Wah Chan, Joann Ater. (2005) Flow cytometry and fluorescence in situ hybridization to detect residual neuroblastoma cells in bone marrow. Pediatric Blood & Cancer 45:6, 787-795
CrossRef47
Simona Coco, Raffaella Defferrari, Paola Scaruffi, Andrea Cavazzana, Claudio Di Cristofano, Luca Longo, Katia Mazzocco, Patrizia Perri, Claudio Gambini, Stefano Moretti, Stefano Bonassi, Gian Paolo Tonini. (2005) Genome analysis and gene expression profiling of neuroblastoma and ganglioneuroblastoma reveal differences between neuroblastic and Schwannian stromal cells. The Journal of Pathology 207:3, 346-357
CrossRef48
Wendy B. London, Luca Boni, Thorsten Simon, Frank Berthold, Clare Twist, Mary Lou Schmidt, Robert P. Castleberry, Katherine K. Matthay, Susan L. Cohn, Bruno De Bernardi. (2005) The role of age in neuroblastoma risk stratification: the German, Italian, and children's oncology group perspectives. Cancer Letters 228:1-2, 257-266
CrossRef49
Boo Messahel, Sandra Hing, Ruth Nash, Iona Jeffrey, Kathy Pritchard-Jones. (2005) Clinical features of molecular pathology of solid tumours in childhood. The Lancet Oncology 6:6, 421-430
CrossRef50
Idoya Lahortiga, Iria V
zquez, Elena Belloni, Jos
CrossRef51
Victoria Castel, Adela Cañete, Rosa Noguera, . (2005) Neuroblastoma. Clinical and Translational Oncology 7:3, 133-145
CrossRef52
Sanjeev A. Vasudevan, Jed G. Nuchtern. (2005) Gene Profiling of High Risk Neuroblastoma. World Journal of Surgery 29:3, 317-324
CrossRef53
David R. Betts, Ninette Cohen, Kurt E. Leibundgut, Thomas Kühne, Ueli Caflisch, Jeanette Greiner, Luba Traktenbrot, Felix K. Niggli. (2005) Characterization of karyotypic events and evolution in neuroblastoma. Pediatric Blood & Cancer 44:2, 147-157
CrossRef54
John M Maris. (2005) The biologic basis for neuroblastoma heterogeneity and risk stratification. Current Opinion in Pediatrics 17:1, 7-13
CrossRef55
Marija Guc-Scekic, Marina Djurisic, Dragan Djokic, Dragana Vujic, Ivan Milovic, Slavisa Djuricic, Danijela Radivojevic, Tanja Lalic, Milena Djuric. (2005) Prognostic value of clinical, genetic and cytogenetic findings in neuroblastoma patients from Serbia and Montenegro. Genetika 37:3, 271-279
CrossRef56
Richard D. Riley, Alex J. Sutton, Keith R. Abrams, Paul C. Lambert. (2004) Sensitivity analyses allowed more appropriate and reliable meta-analysis conclusions for multiple outcomes when missing data was present. Journal of Clinical Epidemiology 57:9, 911-924
CrossRef57
Yuan-Jia Chen, Alexander Vortmeyer, Zhengping Zhuang, Fathia Gibril, Robert T. Jensen. (2004) X-chromosome loss of heterozygosity frequently occurs in gastrinomas and is correlated with aggressive tumor growth. Cancer 100:7, 1379-1387
CrossRef58
Robert E Goldsby, Katherine K Matthay. (2004) Neuroblastoma. Pediatric Drugs 6:2, 107-122
CrossRef59
Max M. van Noesel, Rogier Versteeg. (2004) Pediatric neuroblastomas: genetic and epigenetic ‘Danse Macabre’. Gene 325, 1-15
CrossRef60
Paola Scaruffi, Stefano Parodi, Katia Mazzocco, Raffaella Defferrari, Vincenzo Fontana, Stefano Bonassi, Gian Paolo Tonini. (2004) Detection of MYCN Amplification and Chromosome 1p36 Loss in Neuroblastoma by cDNA Microarray Comparative Genomic Hybridization. Molecular Diagnosis 8:2, 93-100
CrossRef61
Victoria Castel, Adela Cañete. (2004) A comparison of current neuroblastoma chemotherapeutics. Expert Opinion on Pharmacotherapy 5:1, 71-80
CrossRef62
Manfred Schwab, Frank Westermann, Barbara Hero, Frank Berthold. (2003) Neuroblastoma: biology and molecular and chromosomal pathology. The Lancet Oncology 4:8, 472-480
CrossRef63
Jaume Mora, William L. Gerald, Nai-Kong V. Cheung. (2003) Evolving significance of prognostic markers associated with new treatment strategies in neuroblastoma. Cancer Letters 197:1-2, 119-124
CrossRef64
Naoki Mori, Roberta Morosetti, Hideaki Mizoguchi, H. Phillip Koeffler. (2003) Progression of myelodysplastic syndrome: allelic loss on chromosomal arm 1p. British Journal of Haematology 122:2, 226-230
CrossRef65
John M. Maris, Robert P. Castleberry. (2003) Chemotherapy for Neuroblastoma: Is It All or None?. Journal of Pediatric Hematology/Oncology 25:7, 512-514
CrossRef66
Ruediger Spitz, Barbara Hero, Karen Ernestus, Frank Berthold. (2003) FISH analyses for alterations in chromosomes 1, 2, 3, and 11 define high-risk groups in neuroblastoma. Medical and Pediatric Oncology 41:1, 30-35
CrossRef67
Jan J. Molenaar, Peter van Sluis, Kathy Boon, Rogier Versteeg, Huib N. Caron. (2003) Rearrangements and increased expression of cyclin D1 (CCND1) in neuroblastoma. Genes, Chromosomes and Cancer 36:3, 242-249
CrossRef68
Nobumoto Tomioka, Hirofumi Kobayashi, Hajime Kageyama, Miki Ohira, Yohko Nakamura, Fumiaki Sasaki, Satoru Todo, Akira Nakagawara, Yasuhiko Kaneko. (2003) Chromosomes that show partial loss or gain in near-diploid tumors coincide with chromosomes that show whole loss or gain in near-triploid tumors: Evidence suggesting the involvement of the same genes in the tumorigenesis of high- and low-risk neuroblastomas. Genes, Chromosomes and Cancer 36:2, 139-150
CrossRef69
Howard M Katzenstein. (2003) The Role of Angiogenesis in Neuroblastoma. American Journal of Cancer 2:4, 237-244
CrossRef70
Marina Djurisic, Marija Guc-Scekic, Dragana Djokic, Dragana Vujic, S. Milovic, S. Djurisic, Danijela Radivojevic, Tanja Lalic, Milena Djuric. (2003) Cytogenetic and molecular genetic characterization of 28 Serbian and Montenegrian neuroblastoma patients. Archives of Biological Sciences 55:1-2, 9-14
CrossRef71
Frank Westermann, Manfred Schwab. (2002) Genetic parameters of neuroblastomas. Cancer Letters 184:2, 127-147
CrossRef72
P.A. Vo
CrossRef73
Jaume Mora, William L. Gerald, Jing Qin, Nai-Kong V. Cheung. (2002) Evolving significance of prognostic markers associated with treatment improvement in patients with Stage 4 neuroblastoma. Cancer 94:10, 2756-2765
CrossRef74
T Iehara, M Hamazaki, T Sawada. (2002) Cytogenetic analysis of infantile neuroblastomas by comparative genomic hybridization. Cancer Letters 178:1, 83-89
CrossRef75
Garrett M. Brodeur. (2002) Significance of intratumoral genetic heterogeneity in neuroblastomas. Medical and Pediatric Oncology 38:2, 112-113
CrossRef76
J.F. Cliff, L. Newman, M. Malone, G. Brady, St. J. Crean. (2001) Facial features of widespread neuroblastoma: a case report. International Journal of Paediatric Dentistry 11:3, 215-220
CrossRef77
Ying Zhang Chen, Eiichi Soeda, Hong Wei Yang, Junko Takita, Ling Chai, Akira Horii, Johji Inazawa, Misao Ohki, Yasuhide Hayashi. (2001) Homozygous deletion in a neuroblastoma cell line defined by a high-density STS map spanning human chromosome band 1p36. Genes, Chromosomes and Cancer 31:4, 326-332
CrossRef78
Ninette Cohen, David R. Betts, Luba Trakhtenbrot, Felix K. Niggli, Ninette Amariglio, Frida Brok-Simoni, Gideon Rechavi, Dafna Meitar. (2001) Detection of unidentified chromosome abnormalities in human neuroblastoma by spectral karyotyping (SKY). Genes, Chromosomes and Cancer 31:3, 201-208
CrossRef79
Nicole Spieker, Mabel Beitsma, Peter Van Sluis, Alvin Chan, Huib Caron, Rogier Versteeg. (2001) Three chromosomal rearrangements in neuroblastoma cluster within a 300-kb region on 1p36.1. Genes, Chromosomes and Cancer 31:2, 172-181
CrossRef80
Ying Zhang Chen, Yasuhide Hayashi, Jian Guo Wu, Ei-ichiro Takaoka, Kohei Maekawa, Naoki Watanabe, Johji Inazawa, Fumie Hosoda, Yasuhito Arai, Misao Ohki, Hiroshi Mizushima, Aiko Morohashi, Miki Ohira, Akira Nakagawara, Si-Yuan Liu, Masato Hoshi, Akira Horii, Eiichi Soeda. (2001) A BAC-Based STS-Content Map Spanning a 35-Mb Region of Human Chromosome 1p35–p36. Genomics 74:1, 55-70
CrossRef81
Kim Vettenranta, Yan Aalto, Sakari Wikström, Sakari Knuutila, Ulla Saarinen-Pihkala. (2001) Comparative genomic hybridization reveals changes in DNA-copy number in poor-risk neuroblastoma. Cancer Genetics and Cytogenetics 125:2, 125-130
CrossRef82
John M. Maris, Chun Guo, Peter S. White, Michael D. Hogarty, Patricia M. Thompson, Daniel O. Stram, Robert Gerbing, Katherine K. Matthay, Robert C. Seeger, Garrett M. Brodeur. (2001) Allelic deletion at chromosome bands 11q14-23 is common in neuroblastoma. Medical and Pediatric Oncology 36:1, 24-27
CrossRef83
P.F. Ambros, I.M. Ambros, R. Kerbl, A. Luegmayr, S. Rumpler, R. Ladenstein, G. Amann, H. Kovar, E. Horcher, B. De Bernardi, J. Michon, H. Gadner. (2001) Intratumoural heterogeneity of 1p deletions andMYCN amplification in neuroblastomas. Medical and Pediatric Oncology 36:1, 1-4
CrossRef84
Michael D. Hogarty, John M. Maris, Peter S. White, Chun Guo, Garrett M. Brodeur. (2001) Analysis of genomic imprinting at 1p35-36 in neuroblastoma. Medical and Pediatric Oncology 36:1, 52-55
CrossRef85
Freimut H. Schilling, Peter F. Ambros, Heiner Bihl, Tommy Martinsson, Inge M. Ambros, Per Borgstr
CrossRef86
Ruth Ladenstein, Inge M. Ambros, Ulrike P
CrossRef87
John M. Maris, Chun Guo, David Blake, Peter S. White, Michael D. Hogarty, Patricia M. Thompson, Vasanthi Rajalingam, Robert Gerbing, Daniel O. Stram, Katherine K. Matthay, Robert C. Seeger, Garrett M. Brodeur. (2001) Comprehensive analysis of chromosome 1p deletions in neuroblastoma. Medical and Pediatric Oncology 36:1, 32-36
CrossRef88
G
CrossRef89
Susan A. Burchill, Sally E. Kinsey, Susan Picton, Paul Roberts, C. Ross Pinkerton, Peter Selby, Ian J. Lewis. (2001) Minimal residual disease at the time of peripheral blood stem cell harvest in patients with advanced neuroblastoma. Medical and Pediatric Oncology 36:1, 213-219
CrossRef90
Masato Hoshi, Hiromi O. Shiwaku, Yutaka Hayashi, Yasuhiko Kaneko, Akira Horii. (2000) Deletion mapping of 14q32 in human neuroblastoma defines an 1,100-kb region of common allelic loss. Medical and Pediatric Oncology 35:6, 522-525
CrossRef91
Freimut H. Schilling, Heiner Bihl, Hans Jacobsson, Peter F. Ambros, Tommy Martinsson, Per Borgstr
CrossRef92
Vera van Limpt, Alvin Chan, Huib Caron, Peter Van Sluis, Kathy Boon, Marie-Christine Hermus, Rogier Versteeg. (2000) SAGE analysis of neuroblastoma reveals a high expression of the human homologue of theDrosophila Delta gene. Medical and Pediatric Oncology 35:6, 554-558
CrossRef93
Barbara Hero, Thorsten Simon, Stefanie Horz, Frank Berthold. (2000) Metastatic neuroblastoma in infancy: What does the pattern of metastases contribute to prognosis?. Medical and Pediatric Oncology 35:6, 683-687
CrossRef94
Yasuhiko Kaneko, Alfred G. Knudson. (2000) Mechanism and relevance of ploidy in neuroblastoma. Genes, Chromosomes and Cancer 29:2, 89-95
CrossRef95
Arty R. Coppes-Zantinga, Max J. Coppes. (2000) Pediatric oncology in Amsterdam. Medical and Pediatric Oncology 35:3, 159-162
CrossRef96
Katherine K. Matthay, Daniel Stram. (2000) IS ADJUVANT THERAPY EVER WARRANTED IN LOCALIZED NEUROBLASTOMA. Journal of Pediatric Hematology/Oncology 22:5, 399-402
CrossRef97
Frank Berthold, Barbara Hero. (2000) Neuroblastoma. Drugs 59:6, 1261-1277
CrossRef98
Carlos S. Alvarado, Wendy B. London, A. Thomas Look, Garrett M. Brodeur, Dale H Altmiller, Paul S. Thorner, Vijay V. Joshi, Susan T. Rowe, Michael B. Nash, E. Ide Smith, Robert P. Castleberry, Susan L. Cohn. (2000) Natural History and Biology of Stage A Neuroblastoma: A Pediatric Oncology Group Study. Journal of Pediatric Hematology/Oncology 22:3, 197-205
CrossRef99
Jaume Mora, Nai-Kong V. Cheung, Brian H. Kushner, Michael P. LaQuaglia, Kim Kramer, Melissa Fazzari, Glenn Heller, Lishi Chen, William L. Gerald. (2000) Clinical Categories of Neuroblastoma Are Associated with Different Patterns of Loss of Heterozygosity on Chromosome Arm 1p. The Journal of Molecular Diagnostics 2:1, 37-46
CrossRef100
Nicole Spieker, Mabel Beitsma, Peter van Sluis, Ilja Roobeek, Johan T. den Dunnen, Frank Speleman, Huib Caron, Rogier Versteeg. (2000) An integrated 5-Mb physical, genetic, and radiation hybrid map of a 1p36.1 region implicated in neuroblastoma pathogenesis. Genes, Chromosomes and Cancer 27:2, 143-152
CrossRef101
B. De Moerloose, C. Dhooge, G. Laureys, Y. Benoit, M. Demarche, C. Devalck, D. Plantaz, J. Leroy, J. Philipp
CrossRef102
Massimo Romani, Paola Scaruffi, Ida Casciano, Katia Mazzocco, Crocifissa Lo Cunsolo, Andrea Cavazzana, Claudio Gambini, Luca Boni, Bruno De Bernardi, Gian Paolo Tonini. (1999) Stage-independent expression and genetic analysis oftp73 in neuroblastoma. International Journal of Cancer 84:4, 365-369
CrossRef103
John N. Lukens. (1999) Neuroblastoma in the neonate. Seminars in Perinatology 23:4, 263-273
CrossRef104
Hiroyuki Shimada, Inge M. Ambros, Louis P. Dehner, Jun-ichi Hata, Vijay V. Joshi, Borghild Roald. (1999) Terminology and morphologic criteria of neuroblastic tumors. Cancer 86:2, 349-363
CrossRef105
Hiroyuki Shimada, Inge M. Ambros, Louis P. Dehner, Jun-ichi Hata, Vijay V. Joshi, Borghild Roald, Daniel O. Stram, Robert B. Gerbing, John N. Lukens, Katherine K. Matthay, Robert P. Castleberry. (1999) The International Neuroblastoma Pathology Classification (the Shimada system). Cancer 86:2, 364-372
CrossRef106
Susan L. Cohn. (1999) Diagnosis and Classification of the Small Round-Cell Tumors of Childhood. The American Journal of Pathology 155:1, 11-15
CrossRef107
Misako Hirai, Sadao Yoshida, Hironobu Kashiwagi, Tomonori Kawamura, Tomoyoshi Ishikawa, Michio Kaneko, Haruo Ohkawa, Akira Nakagawara, Masanao Miwa, Kazuhiko Uchida. (1999) 1q23 gain is associated with progressive neuroblastoma resistant to aggressive treatment. Genes, Chromosomes and Cancer 25:3, 261-269
CrossRef108
Bown, Nick, Cotterill, Simon, Łastowska, Maria, O'Neill, Seamus, Pearson, Andrew D.J., Plantaz, Dominique, Meddeb, Mounira, Danglot, Gisele, Brinkschmidt, Christian, Christiansen, Holger, Laureys, Genevieve, Nicholson, James, Bernheim, Alain, Betts, David R., Vandesompele, Jo, Van Roy, Nadine, Speleman, Frank, . (1999) Gain of Chromosome Arm 17q and Adverse Outcome in Patients with Neuroblastoma. New England Journal of Medicine 340:25, 1954-1961
Full Text109
Raymond Taetle, Mikel Aickin, Lita Panda, Julia Emerson, Denise Roe, Floyd Thompson, John Davis, Jeffrey Trent, David Alberts. (1999) Chromosome abnormalities in ovarian adenocarcinoma: II. prognostic impact of nonrandom chromosome abnormalities in 244 cases. Genes, Chromosomes and Cancer 25:1, 46-52
CrossRef110
Werner Hilgers, David J. Tang, Avrahom Y. Sugar, Manu C. Shekher, Ralph H. Hruban, Scott E. Kern. (1999) High-resolution deletion mapping of chromosome arm 1p in pancreatic cancer identifies a major consensus region at 1p35. Genes, Chromosomes and Cancer 24:4, 351-355
CrossRef111
Nico G. Hartwig, Huib N. Caron, Jan C. den Hollander, Simon G.F. Robben, R. Maarten Egeler. (1999) Neuroblastoma 4S with an unfavorable biological marker: What to do?. Medical and Pediatric Oncology 32:4, 294-301
CrossRef112
C.M. Hattinger, S. Rumpler, S. Strehl, I.M. Ambros, A. Zoubek, U. P
CrossRef113
Gerald M. Haase, Carlos Perez, James B. Atkinson. (1999) Current aspects of biology, risk assessment, and treatment of neuroblastoma. Seminars in Surgical Oncology 16:2, 91-104
CrossRef114
Yasuhiko Kaneko, Hirofumi Kobayashi, Nobuo Maseki, Akira Nakagawara, Masaharu Sakurai. (1999) Disomy 1 with terminal 1 p deletion is frequent in mass-screening-negative/late-presenting neuroblastomas in young children, but not in mass-screening-positive neuroblastomas in infants. International Journal of Cancer 80:1, 54-59
CrossRef115
Garrett M. Brodeur, Peter F. Ambros, Marie C. Favrot. (1998) Biological aspects of neuroblastoma screening. Medical and Pediatric Oncology 31:5, 394-400
CrossRef116
Valerie A. White, Jeffrey D. Chambers, Paul D. Courtright, Wilma Y. Chang, Douglas E. Horsman. (1998) Correlation of cytogenetic abnormalities with the outcome of patients with uveal melanoma. Cancer 83:2, 354-359
CrossRef117
Daniel A Haber, Eric R Fearon. (1998) The promise of cancer genetics. The Lancet 351, SII1-SII8
CrossRef118
Max M. van Noesel, Karel H
CrossRef119
VIJAY V. JOSHI, GREGORY J. TSONGALIS. (1997) Correlation between Morphologic and Nonmorphologic Prognostic Markers of Neuroblastoma. Annals of the New York Academy of Sciences 824:1 Challenges an, 71-83
CrossRef120
Reinaldo Manhani, Lilian Maria Cristofani, Vicente Filho, Israel Bendit. (1997) Concomitant p53 mutation and MYCN amplification in neuroblastoma. Medical and Pediatric Oncology 29:3, 206-207
CrossRef121
Janet Cowan, Yogeshwar Dayal, Stephen Schwaitzberg, Arthur Tischler. (1997) American Journal of Surgical Pathology 21:8, 957-963
CrossRef122
Rachel A. Altura, John M. Maris, Hao Li, James M. Boyett, Garrett M. Brodeur, A. Thomas Look. (1997) Novel regions of chromosomal loss in familial neuroblastoma by comparative genomic hybridization. Genes, Chromosomes and Cancer 19:3, 176-184
CrossRef123
Reinhold Kerbl, Christian E. Urban, Ruth Ladenstein, Inge M. Ambros, Ekkehard Spuller, Ingomar Mutz, Gabriele Amann, Heinrich Kovar, Helmut Gadner, Peter F. Ambros. (1997) Neuroblastoma screening in infants postponed after the sixth month of age: A trial to reduce “overdiagnosis” and to detect cases with “unfavorable” biologic features. Medical and Pediatric Oncology 29:1, 1-10
CrossRef124
Michel Longy, Bernadette Duboue, Pierre Soubeyran, Daniel Moynet. (1997) Method for the Purification of Tissue DNA Suitable for PCR After Fixation with Bouinʼs Fluid. Diagnostic Molecular Pathology 6:3, 167-173
CrossRef125
F Mitelman. (1997) Clinical significance of cytogenetic findings in solid tumors. Cancer Genetics and Cytogenetics 95:1, 1-8
CrossRef126
CHRISTIAN BRINKSCHMIDT, HOLGER CHRISTIANSEN, HANS JOACHIM TERPE, RONALD SIMON, WERNER BOECKER, FRITZ LAMPERT, STEFAN STOERKEL. (1997) COMPARATIVE GENOMIC HYBRIDIZATION (CGH) ANALYSIS OF NEUROBLASTOMAS—AN IMPORTANT METHODOLOGICAL APPROACH IN PAEDIATRIC TUMOUR PATHOLOGY. The Journal of Pathology 181:4, 394-400
CrossRef127
Garrett M. Brodeur, John M. Maris, Darrell J. Yamashiro, Michael D. Hogarty, Peter S. White. (1997) Biology and Genetics of Human Neuroblastomas. Journal of Pediatric Hematology/Oncology 19:2, 93-101
CrossRef128
Didier Thoraval, Jun-ichi Asakawa, Katharina Wimmer, Rork Kuick, Barbara Lamb, Bruce Richardson, Peter Ambros, Thomas Glover, Samir Hanash. (1996) Demethylation of repetitive DNA sequences in neuroblastoma. Genes, Chromosomes and Cancer 17:4, 234-244
CrossRef129
(1996) Allelic Loss of Chromosome 1p in Neuroblastoma. New England Journal of Medicine 334:24, 1608-1609
Full Text130
Ambros, Ingeborg M., Zellner, AndreaRoald, Borghild, Amann, Gabriele, Ladenstein, Ruth, Printz, DieterGadner, Helmut, Ambros, Peter F., . (1996) Role of Ploidy, Chromosome 1p, and Schwann Cells in the Maturation of Neuroblastoma. New England Journal of Medicine 334:23, 1505-1511
Full Text131
K. Wimmer, Rork Kuick, D. Thoraval, Samir M. Hanash. (1996) Two-dimensional separations of the genome and proteome of neuroblastoma cells. Electrophoresis 17:11, 1741-1751
CrossRef
